Portal de Periódicos da CAPES

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

2009; Taylor & Francis; Volume: 50; Issue: 6 Linguagem: Inglês

10.1080/10428190902926973

1042-8194

Hyun‐Gyung Goh, Yoo‐Jin Kim, Dong‐Wook Kim, Hyeoung‐Joon Kim, Soo‐Hyun Kim, Se‐Eun Jang, Jeong Eon Lee, Dongho Kim, Wan-Seok Kim, Sa-Hee Park, Il‐Young Kweon,

Chronic Lymphocytic Leukemia Research

Although imatinib is considered as a front line therapy in patients with chronic myeloid leukemia (CML), it is still unclear whether transient imatinib discontinuation may adversely affect the outcome. This study was conducted to investigate long-term outcome after discontinuation and resumption of imatinib, and to determine whether intermittent imatinib therapy can be employed in patients with CML. Twenty six Philadelphia chromosome positive (Ph+) patients with CML discontinued imatinib when they achieved complete cytogenetic response (CCyR) or complete molecular response (CMR), and they were retreated with imatinib in case of hematologic, cytogenetic or molecular relapse. Except one patient who progressed and two patients who are in persistent molecular remission without imatinib resumption, all of 23 patients are maintaining the best response achieved after imatinib resumption with a median follow-up of 44 months. This study shows that although imatinib cannot be discontinued completely, intermittent therapy can be considered for the treatment of patients with CML in particular situations.